Human noroviruses are a major global health problem, causing acute gastroenteritis worldwide, and there are currently no specific treatments or vaccines for the disease. However, Baylor College of Medicine researchers have made a significant step forward in understanding the first phase of infection.

In a study published in Nature Communications, the team reports that the globally dominant human norovirus GII.4 strain invades gastrointestinal cells via an unexpected mechanism, providing insight into the viral infection process and highlighting unique pathways and targets for developing effective therapeutics.

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

The researchers focused on the human norovirus pandemic strain GII.4, the one responsible for causing most cases of gastroenteritis worldwide. They worked with human intestinal enteroids, a laboratory model of the human gastrointestinal tract that mimics the strain-specific host-virus infection patterns, making it an ideal system to dissect human norovirus infection, identify strain-specific growth requirements, and develop and test treatments and vaccines.

The team discovered that the binding of human norovirus GII.4 to enteroid cells wounds the cells’ membranes, triggering a membrane repair mechanism to the injury site, which in turn activates another cellular pathway known as the CLIC pathway. The team observed crosstalk between CLIC-mediated internalization of viral particles and host repair mechanisms, proposing that these pathways could be manipulated to interfere with viral entry in human intestinal cells.

The Baylor scientists also discovered novel aspects of how the virus itself participates in the entry process. Previously, it was thought that all interactions between the virus and cells involved only the protruding domain. However, the team found that both the protruding and the shell domains are involved in the entry process, suggesting that virus interactions with cells cause changes in the viral structure that facilitate cell entry.

Globally, most cases of gastroenteritis are caused by GII.4 human norovirus strains with no approved therapies or vaccines available. Recognition of the viral and cellular determinants regulating HuNoV entry provides insight into the infection process of a non-enveloped virus highlighting unique pathways and targets for developing effective therapeutics. These findings provide hope that effective preventive and therapeutic strategies could be developed in the future to combat the global problem of human noroviruses.